← Back to headlines
Gilead to Acquire Cancer Therapy Developer Arcellx for Up to $7.8 Billion
Gilead Sciences has announced its intention to acquire Arcellx, a developer of cancer therapies, in a deal valued at up to $7.8 billion.
23 Feb, 12:52 — 23 Feb, 12:52
Sources
Showing 1 of 1 sources
Related Stories
China Manufacturing Activity Contracts for Second Consecutive Month
40m ago
U.S. Treasury Secretary Bessent Says Yen Movements Remain Contained and Orderly
41m ago
SK On Signs Long-Term Battery Supply Agreement With U.S. Firm NeoVolta Power
1h ago
Aon Nears $17 Billion Acquisition of Insurance Broker USI
5h ago